J&J's guselkumab tops Humira in Phase III psoriasis trial

Johnson & Johnson (NYSE:JNJ) said its anti-IL-23 antibody guselkumab ( CNTO 1959) showed superiority to Humira adalimumab from AbbVie Inc. (NYSE:ABBV) and placebo in the Phase III VOYAGE 1 trial to treat moderate to severe plaque psoriasis.

The 837-patient study's co-primary endpoints compared guselkumab with placebo on the proportion of patients achieving 90% skin clearance as measured by the Psoriasis Area Severity Index (PASI 90), and with cleared or minimal disease defined as a score of 0 or 1 on the Investigator's Global Assessment (IGA) at week 16. Guselkumab met the co-primary endpoints, and also led to significant improvements vs. Humira on both measurements. ...